trending Market Intelligence /marketintelligence/en/news-insights/trending/pidHEjDLlFp7eukZ-gX-4Q2 content esgSubNav
In This List

India's Pfizer to buy AstraZeneca's gastrointestinal drug brand

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


India's Pfizer to buy AstraZeneca's gastrointestinal drug brand

Pfizer Ltd. agreed to acquire the Neksium brand in India from AstraZeneca PLC's Swedish unit AstraZeneca AB for 750 million Indian rupees.

India-based Pfizer said the acquisition of the brand will complement its existing product portfolio in the gastrointestinal therapeutic area.

The closing of the transaction is subject to customary closing conditions.